Cue biopharma enters into a strategic collaboration and option agreement with ono pharmaceutical for cue-401

Boston, feb. 22, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today a collaboration and option agreement with ono pharmaceutical co., ltd. (“ono”), for cue-401, a bispecific protein designed to induce and expand regulatory t cells (tregs) for the treatment of autoimmune and inflammatory diseases.
CUE Ratings Summary
CUE Quant Ranking